Professional Documents
Culture Documents
been demonstrated in association with TGFR1 in bili- been detected in human tumors include gene ampli-
ary, bladder, breast, gastric, liver, ovarian, pancreatic fication leading to receptor overexpression, activating
and prostate cancers. Smad4 mutation, deletion and kinase domain mutations mainly in EGFR, but also
loss of expression has been reported in biliary, blad- in ErbB2, in-frame deletions in the extracellular domain
der, breast, cervical, colon esophageal, intestine, liver, of EGFR (EGFR vIII), and coexpression of ErbB ligands
lung, ovarian and pancreatic cancers. Smad2 de- and receptors in tumors. Each alteration promotes
regulation seems to be less frequent than Smad4, constitutive activation of the receptors.
however mutation and deletion has been observed
CROSS-TALK OF TGF AND EGF
in cervical, colon, liver and lung cancer. Interestingly,
IN CANCER
with the exception of gastric, extravillus trophoblast
Signaling pathways do not act in isolation, but
and colon cancer, Smad3 is often maintained in hu-
interplay with each other and form complex signaling
man carcinomas suggesting that it may have a role
networks. Recent studies have shown that ErbB signal-
different from Smad2 in carcinoma cells that favors
ing, which activates both the MAPK (including Erk1/2,
tumor progression.
JNK1/2/3, and p38/MAPKs) and phosphatidylino-
EGF SIGNALING AND CANCER sitol-3 kinase (PI3K)/Akt pathways, communicates
The epidermal growth factor (EGF) receptor fam- intimately with TGF/Smad in controlling mammary
ily consists of four related receptors: EGFR (EGFR epithelial cell biology and breast cancer development
or ErbB1), ErbB2 (Neu/HER2), ErbB3 (HER3) and [7]. Other common Smad-dependent regulatory
ErbB4 (HER4). These receptors are differently acti- mechanisms include phosphorylation of Smad2 and
vated by ligands including EGF, TGF, amphiregulin Smad3 by PKC and PKG. MAPKs and Akt bind to and/
(SDGF), cellulin (BTC), epiregulin (EREG), heparin- or phosphorylate Smads to control their intracellular
binding EGF-like growth factor (HB-EGF) and the distribution and transcriptional activity [2, 7]. MAPKs
neuregulins (NRG1, NRG2, NRG3 and NRG4) [3, 6]. and Akt also phosphorylate and regulate a variety
Binding of ligands to the extracellular domains of ErbB of Smad binding partners in the nucleus, indirectly
receptors initiates their homodimerization or heterodi- affecting the Smads. We focus below on the cross-talk
merization with other ErbB receptors, and phosphory- involving TGF and Smads from one side, and MAPK
lation of tyrosine residues within their cytoplasmic and Akt from the other side (Fig. 3).
domains. Autophosphorylation of receptors leads
TGF- EGFR
to a number of protein-protein interactions, that in turn
activate downstream growth and survival signals such
as the mitogen-activated protein kinase (MAPK) and PI3K Ras
cytoplasm
phosphoinositol 3-kinase/v-akt murine thymoma viral Smad3 AKT
R-Smad MAP3K
oncogene homolog (PI3K/AKT) pathways (Fig. 2) [6].
EGF ligand P Plag, CNK MAP2K
Smad4 R-Smad
MAPK
EGFR dimer nucleus P
Smad4 R-Smad TF
DNA
Chl P SHP1/2
Fig. 3. Cross-talk between TGF and EGF signaling pathway. The
SRC MAPK and PI3K/Akt are linkers (common targets) of TGF and
Nck-Jnk
EGF pathways. Their interplay is modulated primarily by Smad
functions. MAPKs and Akt bind and/or phosphorylate R-Smads
STAT3/5 to control their intracellular distribution and transcriptional ac-
tivity. MAPKs and Akt also phosphorylate and regulate a variety
PI3K-Akt-mT0R PLC-PKC Ras-Raf-Erk of Smad binding partners in the nucleus, indirectly affecting
the Smads. TGF stimulates Erk1/2 activation by regulating
Fig. 2. Schematic presentation of EGFR signaling pathway. Plag1 and CNK.
EGFR signaling pathway is initiated by binding of ligands to the
extracellular domain of ErbB receptors, which results in receptor
dimerization, tyrosine kinase activation and transphosphoryla-
TGF/SMADS AND THE ERBB/MAPK
tion (P). The activated ErbB receptors are able to interact with PATHWAY
different signaling molecules that transmit the signal in the cell, A consensus is that HER2/Ras can antagonize
including Chl, Src, PI3K, PLC, STAT, Ras, Nck-Jnk and SHP1/2. TGF-induced apoptosis and cell cycle arrest, while al-
The EGF family members play important roles lowing for the pro-migratory and pro-invasive functions
in normal physiological processes including ontogeny, of TGF. Therefore, both positive and negative regu-
morphogenesis, migration, differentiation and prolifer- lations exist between the two pathways. The synergy
ation. Deregulation of EGF family members and related between the TGF and HER2/Ras/MAPK pathways
signaling molecules can contribute to tumorigenesis, often leads to the secretion of TGF, which in turn
invasion and metastasis. In particular, ErbB2 and EGFR promote epithelial-to-mesenchymal transition (EMT)
have been implicated in development of many types and cell invasion, whereas JNK kinases seem to nega-
of human cancer [3, 4, 6]. Genetic changes that have tively regulate the autocrine expression of TGF1 [7,
172 Experimental Oncology 33, 170173, 2011 (September)
8]. MEK/Erk has been reported to positively regulate Akt, consistent with the indispensable function
SMAD3 gene transcription in epithelial and smooth of Smad3 in mediating the pro-apoptotic effects
muscle cells [7]. of TGF. However, exactly how PI3K/Akt modulates
It has been confirmed that the linker region in Smad Smad3 activation remains unanswered.
proteins is important for integrating ErbB/MAPK On the other hand, the PI3K/Akt pathway is also
signals with the TGF pathway. Human cancer cells subjected to TGF regulation. Akt activity increases
overexpressing oncogenic Ras are often resistant in response to TGF treatment, which seems to be re-
to TGF-induced cytostasis. MAPK/Erk-mediates quired for a variety of TGF-induced activities, such
Smad2/3 linker phosphorylation and Smad nuclear as cell migration of HER2-expressing breast cancer
exclusion, which is considered as the reason for the cells, EMT of normal mammary epithelial cells, cell
attenuation of TGF induced cytostasis by MAPK survival of mouse hippocampal neurons and mesen-
[9]. MAPKs (especially Erk1/2) also phosphorylate chymal cells, as well as growth stimulation of certain
the linker of Smad1/5, which almost always blocks fibroblasts [7, 9]. It is to be noted that Akt activation
Smad1/5 nuclear translocation. Phosphorylation by TGF is cell type-dependent and very likely indirect,
in Smad1 linker region by Erk creates a docking site often requiring either MAPKs or autocrine actions
for the Smad1/5-specific E3 ubiquitin ligase, Smurf1. of secreted molecules.
Smurf1 binding not only causes ubiquitination and Alteration of PTEN function represents another
degradation of the Smads but also occludes their route for TGF to influence Akt activity. TGF has
interaction with the nuclear pore complex, thereby been shown to transcriptionally downregulate PTEN
preventing Smad nuclear translocation [9]. In addition in Smad4 null pancreatic cancer cells, which, again,
to R-Smads, MAPKs also phosphorylate and regulate seems to rely on the function of the Ras/MAPK path-
the Co-Smad, Smad4, and the inhibitory Smad7. For way [7, 8, 9]. In the same cells, TGF elicits EMT
instance, MAPK/Erk decreases Smad4 protein stability by dislodging -catenin from the adherence junctions,
[9]. JNK and p38 seem to preferentially phosphorylate a process that involves TGF-dependent PTEN dis-
tumor-derived mutant Smad4 and promote its protea- sociation from -catenin and Akt activation. On the
somal degradation http://www.nature.com/ cr/jour- other hand, TGF/Smad can reduce Akt activity in he-
nal/v19/ n1/full/cr2008302a.html - bib58. Erk, JNK, matopoietic cells by inducing the expression of SHIP
and p38 have all been implicated in the transcriptional (SH2 domain-containing 5 inositol phosphatase),
regulation of Smad7, therefore indirectly regulating a lipid phosphatase that removes the 5 position phos-
TGF signaling. On the flip side, TGF also regulates phate from PIP3.
MAPK/Erk signaling. Addition of TGF stimulates
TARGETING TGF AND EGF PATHWAYS
Erk1/2 activation in most of the cells. Our lab identi-
IN CANCER TREATMENT
fied Plag1 and CNK contribution to TGF induced
The genetic and preclinical studies support target-
Erk1/2 activation [8].
ing TGF signaling as therapeutic strategy for combat-
MAPKs phosphorylate a number of nuclear tran-
ing cancer. To date there have been investigated three
scription factors, many of which can physically interact
approaches to inhibit the TGF signaling. They are:
with Smads and regulate TGF responses. The best-
(1) inhibition at the translational level using antisense
characterized ones in this category are the AP-1 pro-
oligonucleotides, (2) inhibition of the ligand-receptor
teins, including members of the Jun, Fos, Maf, and
interaction using monoclonal antibodies, and (3) in-
ATF sub-families [9]. Functional interaction between
hibition of the receptor-mediated signaling cascade
Smad and the Jun/Fos family proteins has been widely
using inhibitors of TGF receptor kinases [1, 2]. For
studied, and their relationship can be synergistic
each of these approaches, several drugs have been
or antagonistic depending on their target genes and
developed and are either in pre-clinical or in early
other binding partners. Thus, TGF and EGF may
stages of clinical trials. Some of these have already
coordinate their actions by the cross-talk between
been shown to be efficacious in limiting tumor inva-
Smad-dependent signaling and Erk1/2 activation.
sion and metastasis in vivo. Among these drugs are
TGF AND THE ERBB/PI3K/AKT PATHWAY antisence oligos used for treatment of gliomas, and
PI3K pathway promotes cell survival, growth, TR-I kinase inhibitors used for treatment breast
and motility through Akt-mediated phosphorylation cancer. One of the challenges of anti-TGF therapy
of a number of proteins. Oncogenic mutations and will be in targeting the tumor promoting arm of TGF
protein overproduction of PI3K and Akt are commonly signaling while maintaining the tumor suppressive arm.
found in human cancers. The activity of PI3K is coun- EGFR and ErbB receptors have been especially
teracted by the tumor suppressor protein PTEN. Loss- explored as targets for cancer treatments, because
of-function mutations of PTEN also occur at a high overexpression and mutations of these receptors
frequency in human cancers [7]. are frequently observed in human malignancies.
The PI3K/Akt activity is known to alleviate TGF- A variety of small molecule kinase inhibitors target-
induced apoptosis and/or cell cycle arrest in multiple ing EGFR (e.g. erlotinib: Tarceva) and monoclonal
types of cells. Interestingly, Smad3, but not Smad2, antibodies targeting EGFR (e.g. cetuximab: Erbitux)
seems to be the primary target of inhibition by PI3K/ and HER2 (e.g. trastuzumab: Herceptin) have been
Experimental Oncology 33, 170173, 2011 (September) 173
developed and some of them are used for treatment EGF and TGF or development of drugs targeting com-
of lung and breast cancer [3]. Anti-EGFR therapy has mon components of both pathways may confer better
shown significant efficacy for some patients. However, therapeutic effects than single treatments.
no therapeutic response was seen in high number
ACKNOWLEDGEMENT
of other cancer patients. In addition, patients initially
This work was supported by the Swedish Research
responsive to anti-EGFR therapy develop resistance
Council, the Swedish Institute, and the Swedish Can-
over time of treatment. Potential mechanisms of re-
cer Foundation to S.S.
sistance to EGFR-targeted therapy may be depen-
dent on EGFR gene amplification and mutations, and REFERENCES
on activation of alternative signaling pathways which 1. ten Dijke P, Hill CS. New insights into TGF--Smad
bypass the EGFR pathway. signalling. Trends Biochem Sci 2004; 29: 26573.
Using targeted agents to inhibit multiple signaling 2. Massagu J. TGF in cancer. Cell 2008; 134: 21530.
3. Scaltriti M, Baselga J. The epidermal growth factor
pathways has emerged as a new paradigm for antican-
receptor pathway: a model for targeted therapy. Clin Cancer
cer treatment. This approach is based on preclinical Res 2006; 12: 526872.
and clinical data showing potent anti-tumor activity 4. Lurje G, Lenz HJ. EGFR signaling and drug discovery.
of single drugs inhibiting multiple molecular targets Oncology 2009; 77: 40010.
or combination therapies involving multiple drugs with 5. Derynck R, Zhang YE. Smad-dependent and Smad-
selective or narrow target specificity [10]. In a study independent pathways in TGF-beta family signalling. Nature
comparing the multi-targeting tyrosine kinase in- 2003; 425: 57784.
6. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal
hibitor SU11248whose targets include VEGFR and
growth factor-related peptides and their receptors in human
PDGFRwith agents targeting only PDGFR (imatinib) malignancies. Crit Rev Oncol Hematol 1995; 19: 183232.
or VEGFR (SU10944) in mouse xenograft models, 7. Kretzschmar M, Doody J, Timokhina I, et al. A mecha-
the most robust anti-tumor and anti-angiogenic ef- nism of repression of TGFbeta/Smad signaling by oncogenic
fects were observed with SU11248. Moreover, the Ras. Genes Dev 1999; 13: 80416.
efficacy of imatinib combined with SU10944 was 8. Bhaskaran N, Souchelnytskyi S. Systemic analysis of
generally similar to that of SU11248 monotherapy, TGFbeta proteomics revealed involvement of Plag1/CNK1/
suggesting that the anti-tumor and anti-angiogenic RASSF1A/Src network in TGFbeta1-dependent activation of
Erk1/2 and cell proliferation. Proteomics 2008; 8: 450720.
effects of SU11248 included additional effects related
9. Guo X, Wang XF. Signaling cross-talk between TGF-/
to VEGFR and PDGFR inhibition [10]. This suggests BMP and other pathways. Cell Research 2009; 19: 7188.
that optimal therapeutic approaches to cancer may in- 10. Faivre S, Djelloul S, Raymond E. New paradigms in
volve targeting multiple molecules in different signaling anticancer therapy: targeting multiple signaling pathways with
pathways. Therefore, combination of drugs targeting kinase inhibitors. Semin Oncol 2006; 33: 40720.